{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:59:11Z","timestamp":1789401551538,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031934","name":"First Affiliated Hospital of Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["2024-MS-17"],"award-info":[{"award-number":["2024-MS-17"]}],"id":[{"id":"10.13039\/100031934","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-YBSF-320"],"award-info":[{"award-number":["2023-YBSF-320"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["xzy012022129"],"award-info":[{"award-number":["xzy012022129"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003642"],"award-info":[{"award-number":["82003642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jare.2025.10.061","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:19:49Z","timestamp":1761646789000},"page":"1175-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4734-4428","authenticated-orcid":false,"given":"Yun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6242-0129","authenticated-orcid":false,"given":"Hong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-5707","authenticated-orcid":false,"given":"Bingyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5656-8020","authenticated-orcid":false,"given":"Bohan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2025.10.061_b0005","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jare.2025.10.061_b0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/aje\/kwaa215","article-title":"Trends in acute lymphoblastic leukemia incidence in the United States by race\/ethnicity from 2000 to 2016","volume":"190","author":"Feng","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jare.2025.10.061_b0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1309\/AJCPAN7BH5DNYWZB","article-title":"B-acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"144","author":"Loghavi","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jare.2025.10.061_b0020","doi-asserted-by":"crossref","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology 2014, the American Society of Hematology Education Program Book 2016, 580-588 (2016).","DOI":"10.1182\/asheducation-2016.1.580"},{"key":"10.1016\/j.jare.2025.10.061_b0025","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/modpathol.3800128","article-title":"Mature B-cell acute lymphoblastic leukemia with t (9; 11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia","volume":"17","author":"Tsao","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jare.2025.10.061_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.jare.2025.10.061_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.710163","article-title":"Long-term effects of pediatric acute lymphoblastic leukemia chemotherapy: can recent findings inform old strategies?","volume":"11","author":"Al-Mahayri","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2025.10.061_b0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/jpm11080715","article-title":"Targeted therapy in acute lymphoblastic leukaemia","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Personalized Med"},{"key":"10.1016\/j.jare.2025.10.061_b0045","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3390\/cancers14082021","article-title":"Recent advances in treatment options for childhood acute lymphoblastic leukemia","volume":"14","author":"Malczewska","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jare.2025.10.061_b0050","first-page":"106","article-title":"Recent advances in adult acute lymphoblastic leukemia","volume":"14","author":"Richard-Carpentier","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jare.2025.10.061_b0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11912-008-0070-3","article-title":"Relapsed acute lymphoblastic leukemia: current status and future opportunities","volume":"10","author":"Harned","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jare.2025.10.061_b0060","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s43018-020-00124-1","article-title":"Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia","volume":"1","author":"Oshima","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0065","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jare.2025.10.061_b0070","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/EDBK_280175","article-title":"Recent advances in managing acute lymphoblastic leukemia","volume":"40","author":"DeAngelo","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jare.2025.10.061_b0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.33298","article-title":"Long\u2010term survival of patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"127","author":"Topp","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41419-020-2388-1","article-title":"Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in chinese relapsed or refractory B cell acute lymphoblast leukemia patients","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jare.2025.10.061_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","article-title":"T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies","volume":"2","author":"Cordo'","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.jare.2025.10.061_b0090","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.3390\/ijms22094502","article-title":"The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia","volume":"22","author":"Lato","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2025.10.061_b0095","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jare.2025.10.061_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1139367","article-title":"Aurora kinases: generators of spatial control during mitosis","volume":"11","author":"Ali","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jare.2025.10.061_b0110","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1158\/1078-0432.CCR-06-1405","article-title":"Aurora kinases: new targets for cancer therapy","volume":"12","author":"Carvajal","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.10.061_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0120","doi-asserted-by":"crossref","first-page":"e7718","DOI":"10.7717\/peerj.7718","article-title":"AURKB: a promising biomarker in clear cell renal cell carcinoma","volume":"7","author":"Wan","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.jare.2025.10.061_b0125","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.gyobfe.2009.04.002","article-title":"Function of aurora kinase C (AURKC) in human reproduction","volume":"37","author":"Harbuz","year":"2009","journal-title":"Gyn\u00e9cologie, Obst\u00e9trique & Fertilit\u00e9"},{"key":"10.1016\/j.jare.2025.10.061_b0130","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/molecules26071981","article-title":"Aurora kinase B inhibition: a potential therapeutic strategy for cancer","volume":"26","author":"Borah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jare.2025.10.061_b0135","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1073\/pnas.1816254116","article-title":"Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia","volume":"116","author":"Poulard","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jare.2025.10.061_b0140","doi-asserted-by":"crossref","first-page":"21272","DOI":"10.1038\/s41598-020-78024-8","article-title":"Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia","volume":"10","author":"Moreira-Nunes","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2025.10.061_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.01.001","article-title":"Direct phosphorylation and stabilization of MYC by aurora B kinase promote T-cell leukemogenesis","volume":"37","author":"Jiang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2025.10.061_b0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/BS9.0000000000000046","article-title":"MYC degradation via AURKB inhibition: a new brake in the path to T-ALL","volume":"2","author":"Zhang","year":"2020","journal-title":"Blood Sci"},{"key":"10.1016\/j.jare.2025.10.061_b0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CAD.0000000000000684","article-title":"Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells","volume":"30","author":"He","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jare.2025.10.061_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112589","article-title":"Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression","volume":"203","author":"Lakkaniga","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2025.10.061_b0165","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/1535-7163.MCT-09-0041","article-title":"GSK1070916, a potent Aurora B\/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models","volume":"8","author":"Hardwicke","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2025.10.061_b0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2012.652303","article-title":"Danusertib, an aurora kinase inhibitor","volume":"21","author":"Meulenbeld","year":"2012","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.jare.2025.10.061_b0175","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.1158\/0008-5472.CAN-10-3001","article-title":"Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines","volume":"70","author":"Payton","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2025.10.061_b0180","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41416-023-02185-2","article-title":"Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours","volume":"128","author":"Johnson","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jare.2025.10.061_b0190","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","article-title":"Targeting selective autophagy by AUTAC degraders","volume":"16","author":"Takahashi","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.jare.2025.10.061_b0195","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41422-021-00532-7","article-title":"Degradation of lipid droplets by chimeric autophagy-tethering compounds","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.jare.2025.10.061_b0200","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jare.2025.10.061_b0205","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jare.2025.10.061_b0210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0215","unstructured":"Gao X, et al. (American Society of Clinical Oncology, 2022)."},{"key":"10.1016\/j.jare.2025.10.061_b0220","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-GS3-03","article-title":"Abstract GS3-03: GS3-03 ARV-471, a PROTAC\u00ae estrogen receptor (ER) degrader in advanced ER-positive\/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1\/2 study","volume":"83","author":"Schott","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2025.10.061_b0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jare.2025.10.061_b0230","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202104850","article-title":"Kill two birds with one stone: a multifunctional dual\u2010targeting protein drug to overcome imatinib resistance in philadelphia chromosome\u2010positive leukemia","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci"},{"key":"10.1016\/j.jare.2025.10.061_b0235","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201859","article-title":"De novo design of an androgen receptor DNA binding domain\u2010targeted peptide PROTAC for prostate cancer therapy","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci"},{"key":"10.1016\/j.jare.2025.10.061_b0240","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/jacsau.3c00795","article-title":"Development of a double-stapled peptide stabilizing both \u03b1-helix and \u03b2-sheet structures for degrading transcription factor AR-V7","volume":"4","author":"Ma","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.jare.2025.10.061_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105212","article-title":"Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy","volume":"105","author":"Zhang","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jare.2025.10.061_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105162","article-title":"Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response","volume":"104","author":"Xu","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jare.2025.10.061_b0255","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1750-3639.2012.00633.x","article-title":"A urora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma","volume":"23","author":"Buczkowicz","year":"2013","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jare.2025.10.061_b0260","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12885-017-3103-1","article-title":"Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemia","volume":"17","author":"Chow","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jare.2025.10.061_b0265","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nn.3637","article-title":"Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation","volume":"17","author":"Fan","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jare.2025.10.061_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202319232","article-title":"Targeted degradation of cell\u2010surface proteins via chaperone\u2010mediated autophagy by using peptide\u2010conjugated antibodies","volume":"63","author":"Shao","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.jare.2025.10.061_b0275","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1021\/acschembio.4c00092","article-title":"A novel lysosome targeting chimera for targeted protein degradation via split-and-mix strategy","volume":"19","author":"Wang","year":"2024","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jare.2025.10.061_b0280","article-title":"Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies","volume":"6","author":"Lemay","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jare.2025.10.061_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108376","article-title":"Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis","volume":"787","author":"Marima","year":"2021","journal-title":"Mutation Research\/Reviews in Mutation Research"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225008562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225008562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:43:12Z","timestamp":1782330192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225008562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"alternative-id":["S2090123225008562"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.10.061","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.10.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}